Last reviewed · How we verify
NCT06914726: PC-CDS
Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
NA trial testing Patient Centered Clinical Decision Support (PC-CDS) in Hereditary Breast/Ovarian Cancer (brca1, brca2) in 2,488 participants. Enrolling by invitation.
30 June 2028
Quick facts
| Lead sponsor | HealthPartners Institute |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 2,488 |
| Start date | 9 July 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patient Centered Clinical Decision Support (PC-CDS)
Conditions studied
- Hereditary Breast/Ovarian Cancer (brca1, brca2) — all drugs for Hereditary Breast/Ovarian Cancer (brca1, brca2) →
- Lynch Syndrome — all drugs for Lynch Syndrome →
- Genetic Variation — all drugs for Genetic Variation →
- HBOC Syndrome — all drugs for HBOC Syndrome →
Sponsor
HealthPartners Institute
Who can join
18 and older, any sex, with Hereditary Breast/Ovarian Cancer (brca1, brca2) or Lynch Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to address care gaps for participants at high risk of breast and ovarian cancer (HBOC), or Lynch syndrome (LS) because of testing positive for specific genetic variants. A patient-centered clinical decision support (PC-CDS) tool will help identify participants with genetic variations and display recommendations for referrals and testing to the clinician and participant at a primary care visit. The main question the study aims to answer is: \- Does clinical decision support for participants with hereditary cancer syndromes improve the use of evidence-based cancer prevention care. Participants being seen in the PC-CDS group are compared to participants being seen in usual care (UC) to see if they are up to date on guideline-based cancer prevention care and to see if participants in the PC-CDS group report more shared decision making and higher rates of self-management of their genetic cancer risks. Participants will be asked to answer survey questions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06914726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other HealthPartners Institute trials
Trials by the same sponsor.
- NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei · NA · not yet recruiting
- NCT07354919 — Axelopran in Advanced Cancers · Phase 2 · not yet recruiting
- NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age · Phase 1 · withdrawn
- NCT06999330 — TMS in Anxiety-Parkinson's Disease · NA · enrolling by invitation
- NCT06991192 — ACL Reconstruction Rehabilitation With Exercise and Psychological Support · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06914726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06914726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing